Markers of Systemic Inflammation May Aid Diabetes Risk Prediction
By Lori Solomon HealthDay Reporter
TUESDAY, March 5, 2024 -- Cumulative high-sensitivity C-reactive protein (CumCRP) and monocyte-to-high-density lipoprotein ratio (CumMHR) both independently and jointly are associated with an increased risk for type 2 diabetes (T2D), according to a study published online Jan. 28 in the Journal of Translational Medicine.
Dan Wu, M.B.B.S., Ph.D., from the First Affiliated Hospital of Shantou University Medical College in China, and colleagues investigated the association between systemic inflammation assessed by joint CumCRP and CumMHR and incident T2D. The analysis included 40,813 nondiabetic participants followed for a median 7.98 years.
The researchers found that CumMHR and CumCRP either alone or jointly were associated with incident T2D after adjusting for potential confounders. In each CumCRP strata, high CumMHR levels significantly increased the risk for incident T2D (P-interaction = 0.0278). Simultaneous elevations in CumMHR and CumCRP levels carried the highest risk (adjusted hazard ratio, 1.71) compared with both in the low strata. The coexposure risk was modified by age, sex, hypertension, dyslipidemia, and prediabetes status. When CumMHR and CumCRP were added into the multivariable-adjusted model, C-statistics increased from 0.7377 to 0.7417, with a net reclassification improvement of 12.39 percent.
"In light of our findings, ongoing monitoring of the MHR and high-sensitivity CRP levels over time might provide a supplemental method for the early determination of the risk of type 2 diabetes, especially for individuals at low risk defined by traditional risk factors," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.